Zai Lab Ltd (ZLAB)

NASDAQDrugs and biotech company based in Shanghai.

Why it is here: Sales grew 15% in 2025, from $399 million to $460 million. The company is not profitable yet, so this is a smaller, higher risk company to study, not a pick. Based on data the company filed with the SEC.

Snapshot

-$176 millionNet income 2025

-$257 millionNet income 2024

n/aNet income 2023

$460 millionRevenue 2025 (+15.3% vs 2024)

$1.2 billionTotal assets

Price chart

Latest filings and news from the company

These links go to the company’s own filings on SEC EDGAR. An 8-K is often how a company announces news.

Quarterly report (10-Q)2026-11-05
Current report (8-K), often a press release or news2026-11-05
Current report (8-K), often a press release or news2026-10-23
Quarterly report (10-Q)2026-08-06
Current report (8-K), often a press release or news2026-08-06

About Zai Lab Ltd

Zai Lab Ltd is listed on the Nasdaq under the ticker ZLAB. The SEC classifies its main business as Pharmaceutical Preparations. Its fiscal year ends on December 31.

What this kind of business does

Drug and biotech companies research, test and sell medicines. Some sell approved products, others work on drugs still in testing.

What to look at

Results depend on trials, approvals and patents. An investor may want to look at what is in the pipeline, when patents end, and how much cash the company has.

Topics

Drugs and biotech companies Profitable 3 years running StockVert

Similar companies

Johnson & Johnson (JNJ)AbbVie Inc (ABBV)Merck & Co., Inc (MRK)Amgen Inc (AMGN)Gilead Sciences, Inc (GILD)

For education only. This is not advice to buy or sell. Figures come from the company’s SEC filings for fiscal years 2023 to 2025 and are shown as filed. Chart provided by TradingView. Always read the company’s own reports.

Positive Stocks

Company Directory